|
|
Post by agedhippie on Jun 5, 2023 16:44:12 GMT -5
...
On a separate topic (i.e., the topic of this thread), a family member started Ozempic over the weekend and only threw up 3 times (so far). The doctor told her that the nausea and vomiting typically goes away after a few days and at most a few weeks. 
agedhippie (and/or others) is there any reason to believe an inhalable version of GLP-1 would reduce the nausea and other side-effects?
Ugh. It's one of the reasons I never took it when my endo prescribed it, I preferred to just take more insulin. I would be interested to know if it does go away and on what timescale. I don't know why it would reduce the side effects because those are mostly related to the gut and I can't see why the delivery would matter. The only test so far was a single shot to see if it hit the blood stream and at what level. It cleared fast so it may not have had time to cause problems before it was gone. There would need to be some engineering to the molecule to make it hang around longer (GLP_1 naturally clears fast), but that's solved science, at which point you would find out about the nausea. Reaching that point would cost money though and Mike might not see that as the best use of resources as there is a risk that you find that it doesn't solve the nausea issue, hence the GLP-1 + Afrezza idea. |
|
|
|
Post by sayhey24 on Jun 5, 2023 17:26:10 GMT -5
With the moms able to track the kids CGM on their phones I don't think the fear factor will work. I am not aware of a single case of severe hypoglycemia where the afrezza user died. Has one even been hospitalized??? I am also not aware of a single case where afrezza caused a lung cancer case since approval. The funny thing on the cough is we never hear about it with Tyvaso DPI so it can't be that bad. I am sure someone can dream up another roadblock. There has to be something but I have no idea what. SAFETY, SAFETY, SAFETY. "It's the SAFETY, stupid."
Can't wait to see how these predictions turn out.
On a separate topic (i.e., the topic of this thread), a family member started Ozempic over the weekend and only threw up 3 times (so far). The doctor told her that the nausea and vomiting typically goes away after a few days and at most a few weeks.
agedhippie (and/or others) is there any reason to believe an inhalable version of GLP-1 would reduce the nausea and other side-effects?
We have the TS GLP1 Phase 1a trial which showed TS GLP1 did not show the same nausea and vomiting as the oral or subq. In the article it even says GLP-1 plasma concentrations peaked very quickly, with a max occurring less than 3 minutes after inhalation. Even in subjects that achieved plasma GLP-1 concentrations in excess of 100 pmol/L, the nausea and vomiting characteristically associated with such levels was not observed. It also says - "As well, with pulsatile delivery, we may potentially avoid unusual adverse effects such as the acute pancreatitis that has been described with presently marketed GLP analogues." www.diabetesincontrol.com/positive-results-for-inhaled-glp-1-cpd/I love it " at most a few weeks". I bet by that time they have lost 20 pounds. IDK, doing a Phase 2/3 on this seems like a no-brainer to me. I would sure like to know why we are not. |
|
|
|
Post by cretin11 on Jun 5, 2023 17:54:22 GMT -5
sayhey what’s your best guess (as to why we are not)?
|
|
|
|
Post by sayhey24 on Jun 6, 2023 6:21:07 GMT -5
sayhey what’s your best guess (as to why we are not)? To be honest, I have been waiting for Mike to make an announcement. I am hoping he has been using his new phone and making a deal but IDK. There is no question the market for GLP1s in the diet space has exploded. I think this caught him off guard and I am not sure if he knew about TS GLP1 until last year. I also think going up against BP in the GLP1 space scares him a bit. For years we have been asking for the afrezza/GLP1 trial for the diabetes space. We still don't have that but we do have Mike now saying its coming. At this point the diet market for GLP1s just seems so large for an easy to use drug which minimizes the nausea. It makes ignoring TS GLP1 very difficult. Either TS GLP1 is as good as Peter Richardson thought or its not. We as shareholders need to know this ASAP. The Phase 1 trial showed such promise. If its no good then we need to know and why its no good. If its half as good as Peter thought not moving forward at lightning speed seems like corporate malpractice. |
|
|
|
Post by mango on Jun 6, 2023 9:25:19 GMT -5
The Technosphere GLP-1 Phase 1 results are good enough to warrant further investigation into the asset. If we are to maintain an Endocrine Business Unit then we need to expand the assets in that unit. Technosohere GLP-1 would make for an attractive asset and revenues, and perhaps interest BP to want to partner. The data is promising, potentially curtailing the horrific side effects so often seen with today's GLP-1 injectables.
|
|
|
|
Post by peppy on Jun 6, 2023 9:50:00 GMT -5
The Technosphere GLP-1 Phase 1 results are good enough to warrant further investigation into the asset. If we are to maintain an Endocrine Business Unit then we need to expand the assets in that unit. Technosohere GLP-1 would make for an attractive asset and revenues, and perhaps interest BP to want to partner. The data is promising, potentially curtailing the horrific side effects so often seen with today's GLP-1 injectables. The question comes to why? Listening to this WAPO gift article, this reporter lost 40 pounds on Ozempic and the injection was .25 a ml or cubic centimeter which ever way you look at it. Her attitude was, the injection was easy enough. "Start OZEMPIC® with a 0.25 mg subcutaneous injection once weekly for 4 weeks. The 0.25 mg dosage is intended for treatment initiation and is not effective for glycemic control." www.novo-pi.com/ozempic.pdfOpinion I lost 40 pounds on Ozempic. But I’m left with even more questions. wapo.st/43GikT6She was thrilled. 1,000 dollars a month by employer insurer. Interesting she touched on the slightly different efficiency of MOUNJARO to lose more weight. "12.1 Mechanism of Action Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1. Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner. OZEMPIC® (semaglutide) injection, for subcutaneous use, contains semaglutide, a human GLP-1 receptor agonist (or GLP-1 analog). The peptide backbone is produced by yeast fermentation. The main protraction mechanism of semaglutide is albumin binding, facilitated by modification of position 26 lysine with a hydrophilic spacer and a C18 fatty di-acid. Furthermore, semaglutide is modified in position 8 to provide stabilization against degradation by the enzyme dipeptidyl-pepti- dase 4 (DPP-4). A minor modification was made in position 34 to ensure the attachment of only one fatty di-acid. The molecular formula is C187H291N45O59 and the molecular weight is 4113.58 g/mol. Additionally there is an oral "The U.S. Food and Drug Administration today approved Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along with diet and exercise. Rybelsus is the first glucagon-like peptide (GLP-1) receptor protein treatment approved for use in the United States that does not need to be injected. GLP-1 drugs are non-insulin treatments for people with type 2 diabetes." |
|
|
|
Post by mango on Jun 6, 2023 10:07:31 GMT -5
The Technosphere GLP-1 Phase 1 results are good enough to warrant further investigation into the asset. If we are to maintain an Endocrine Business Unit then we need to expand the assets in that unit. Technosohere GLP-1 would make for an attractive asset and revenues, and perhaps interest BP to want to partner. The data is promising, potentially curtailing the horrific side effects so often seen with today's GLP-1 injectables. The question comes to why? Listening to this WAPO gift article, this reporter lost 40 pounds on Ozempic and the injection was .25 a ml or cubic centimeter which ever way you look at it. Her attitude was, the injection was easy enough. "Start OZEMPIC® with a 0.25 mg subcutaneous injection once weekly for 4 weeks. The 0.25 mg dosage is intended for treatment initiation and is not effective for glycemic control." www.novo-pi.com/ozempic.pdfOpinion I lost 40 pounds on Ozempic. But I’m left with even more questions. wapo.st/43GikT6She was thrilled. 1,000 dollars a month by employer insurer. Interesting she touched on the slightly different efficiency of MOUNJARO to lose more weight. "12.1 Mechanism of Action Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1. Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner. OZEMPIC® (semaglutide) injection, for subcutaneous use, contains semaglutide, a human GLP-1 receptor agonist (or GLP-1 analog). The peptide backbone is produced by yeast fermentation. The main protraction mechanism of semaglutide is albumin binding, facilitated by modification of position 26 lysine with a hydrophilic spacer and a C18 fatty di-acid. Furthermore, semaglutide is modified in position 8 to provide stabilization against degradation by the enzyme dipeptidyl-pepti- dase 4 (DPP-4). A minor modification was made in position 34 to ensure the attachment of only one fatty di-acid. The molecular formula is C187H291N45O59 and the molecular weight is 4113.58 g/mol. Additionally there is an oral "The U.S. Food and Drug Administration today approved Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along with diet and exercise. Rybelsus is the first glucagon-like peptide (GLP-1) receptor protein treatment approved for use in the United States that does not need to be injected. GLP-1 drugs are non-insulin treatments for people with type 2 diabetes." If we can develop a safer drug without all the horrific side effects then why not? MannKind obviously saw potential with it hence the Phase 1 trial. How efficacious is the oral formulation? How's it safety profile and post marketing adverse events? |
|
|
|
Post by uvula on Jun 6, 2023 10:15:19 GMT -5
Ozempic is very popular. All of us who have never used the drug should probably stop claiming the side effects are terrible and/or horrible. Every drug data sheet lists every potential side effect, including Afrezza. The reality is that many people like it.
|
|
|
|
Post by mango on Jun 6, 2023 10:31:07 GMT -5
Ozempic is very popular. All of us who have never used the drug should probably stop claiming the side effects are terrible and/or horrible. Every drug data sheet lists every potential side effect, including Afrezza. The reality is that many people like it. The reality is it comes with a very serious Black Box Warnings, along with serious potential side effects and also horrific post marketing adverse events. I have not seen a single social media post praising this drug. I know why. |
|
|
|
Post by peppy on Jun 6, 2023 11:14:22 GMT -5
Ozempic is very popular. All of us who have never used the drug should probably stop claiming the side effects are terrible and/or horrible. Every drug data sheet lists every potential side effect, including Afrezza. The reality is that many people like it. The reality is it comes with a very serious Black Box Warnings, along with serious potential side effects and also horrific post marketing adverse events. I have not seen a single social media post praising this drug. I know why. Good point. The author of that Post opinion article, didn't even mention the black box warning the threat of thyroid cancer. Seems she didn't care. She did mention the adverse side effects that took other weight loss medications off the market. .25 cc once a week subq, how could fast entry into the systemic circulation make that safer? It sounds to me she had a pen. .25 cc. a mosquito bite. |
|
|
|
Post by hellodolly on Jun 6, 2023 11:47:51 GMT -5
Why not do the work needed and target the kids who are obese? Once the kids start taking it, the adults will, too.
|
|
|
|
Post by peppy on Jun 6, 2023 12:01:04 GMT -5
Why not do the work needed and target the kids who are obese? Once the kids start taking it, the adults will, too. 1 INDICATIONS AND USAGE OZEMPIC® is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. www.novo-pi.com/ozempic.pdfPerhaps I miss understood what was being asked. |
|
|
|
Post by sayhey24 on Jun 6, 2023 12:45:40 GMT -5
Ozempic is very popular. All of us who have never used the drug should probably stop claiming the side effects are terrible and/or horrible. Every drug data sheet lists every potential side effect, including Afrezza. The reality is that many people like it. The reality is it comes with a very serious Black Box Warnings, along with serious potential side effects and also horrific post marketing adverse events. I have not seen a single social media post praising this drug. I know why. What caught my eye when I started the thread was that in the DailyMail article it said there is a Reddit group with more than 30,000 members that has been created where users share their most embarrassing stories. IDK if terrible and/or horrible always describes their stories, maybe just embarrassing. www.dailymail.co.uk/health/article-12119851/People-Ozempic-say-theyre-defecating-bed-symptom-affects-30-takers.htmlGiven the fact that many people as you say "like it", what if we had a solution which provides the diet benefits with less embarrassing stories? What if we just got 10% of the GLP1 diet market? I think at 10% TS GLP1 would dwarf Tyvaso DPI sales and it would provide the 3rd TS compound. Mango - I noticed in the wapo article you posted it mentioned they are looking at GLP1s for Alzheimer's too. Maybe TS GLP1 could have a role here too. |
|
|
|
Post by peppy on Jun 6, 2023 13:05:04 GMT -5
The reality is it comes with a very serious Black Box Warnings, along with serious potential side effects and also horrific post marketing adverse events. I have not seen a single social media post praising this drug. I know why. What caught my eye when I started the thread was that in the DailyMail article it said there is a Reddit group with more than 30,000 members that has been created where users share their most embarrassing stories. IDK if terrible and/or horrible always describes their stories, maybe just embarrassing. www.dailymail.co.uk/health/article-12119851/People-Ozempic-say-theyre-defecating-bed-symptom-affects-30-takers.htmlGiven the fact that many people as you say "like it", what if we had a solution which provides the diet benefits with less embarrassing stories? What if we just got 10% of the GLP1 diet market? I think at 10% TS GLP1 would dwarf Tyvaso DPI sales and it would provide the 3rd TS compound. Mango - I noticed in the wapo article you posted it mentioned they are looking at GLP1s for Alzheimer's too. Maybe TS GLP1 could have a role here too. Why TS GLP1? Tell me why? “If every obese American were on semaglutide at its current price of $15,000 a year, the total cost would be roughly 10 percent of the entire U.S. economy, or $2.1 trillion. That’s not going to happen.” Already, the impact is quantifiable — and enormous. Komodo Health, which tracks health-care data, reported in February that in 2022 “more than 5 million prescriptions for Ozempic, Mounjaro, Rybelsus , or Wegovy were written for weight management, compared with just over 230,000 in 2019 — a 2,082% increase.” No surprise: These patients, with no prior history of diabetes, were also overwhelmingly female — 81 percent of those ages 25 to 44.
|
|
|
|
Post by sayhey24 on Jun 6, 2023 13:51:54 GMT -5
|
|
